Inhibition of antiapoptotic proteins as a monotherapy, (specifically Bcl-2, Bcl-xL, and Mcl-1) is a successful cancer treatment strategy for acute myeloid leukemia, chronic lymphocytic leukemia, and small lymphocytic lymphoma (27–30). Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.